title: Effect of brefeldin A and castanospermine on resistant cell lines as supplements in anticancer therapy.
abstract: In the present study, we analyzed the influence of brefeldin A (BFA) and castanospermine (CAS) on the activity, stability and localization of P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) in various resistant cell lines. The impact of BFA and CAS on cell viability was assessed using the MTT test. Western blotting (WB) was performed to assess the effect of the inhibitors on the expression of the investigated proteins. Immunofluorescence was employed to assess the effect of BFA and CAS on the cellular localization of the proteins. Flow cytometry was used to verify the functional role of inhibitors on drug uptake and efflux. The MTT test showed that BFA had a significant effect on cell viability in LoVo/Dx and W1PR cell lines. WB analysis demonstrated that BFA partially blocked Pgp N-glycosylation and induced BCRP degradation and CASP 3-dependent apoptosis in W1TR cells; however, the BFA activity was p53-independent. CAS had no effect on the stability of Pgp but increased the level of non-glycosylated BCRP. The expression of p53 protein decreased in all of the cells that were treated with CAS. Immunofluorescence revealed that BFA caused a more granular Pgp signal in W1PR and BCRP in A2780T1 cells. Furthermore, BFA caused morphological changes in LoVo/Dx and W1TR cell lines. CAS also induced a granular signal in all of the cell lines, except W1TR. The flow cytometry showed higher dye accumulation in sensitive cell lines. We observed an increase in the mean fluorescence intensity (MFI) of Rho123 in LoVo/Dx cells treated with BFA and CAS, but no differences were observed in W1PR. BFA had no effect on the MFI of W1TR, but CAS led to an increase in the level of intracellular H33342 in W1TR and A2780T1 cells. These results suggest that these compounds are likely to be useful as supplements in anticancer therapy.
authors.affiliation: Department of Histology and Embryology, Poznan University of Medical Sciences, 60-781 Poznań, Poland.
authors.forename: Karolina
authors.initials: K
authors.lastname: Wojtowicz
authors.affiliation: Department of Histology and Embryology, Poznan University of Medical Sciences, 60-781 Poznań, Poland.
authors.forename: Radosław
authors.initials: R
authors.lastname: Januchowski
authors.affiliation: Department of Pathophysiology, Poznan University of Medical Sciences, 60-806 Poznań, Poland.
authors.forename: Patrycja
authors.initials: P
authors.lastname: Sosińska
authors.affiliation: Department of Histology and Embryology, Poznan University of Medical Sciences, 60-781 Poznań, Poland.
authors.forename: Michał
authors.initials: M
authors.lastname: Nowicki
authors.affiliation: Department of Histology and Embryology, Poznan University of Medical Sciences, 60-781 Poznań, Poland.
authors.forename: Maciej
authors.initials: M
authors.lastname: Zabel
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism; D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2 / Q000378:metabolism; D000970:Antineoplastic Agents / Q000494:pharmacology*; D020126:Brefeldin A / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D019008:Drug Resistance, Neoplasm; D004354:Drug Screening Assays, Antitumor; D004357:Drug Synergism; D006801:Humans; D007212:Indolizines / Q000494:pharmacology*; D009363:Neoplasm Proteins / Q000378:metabolism; D021381:Protein Transport; D054836:Indolizidines
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D000970:Antineoplastic Agents; D020126:Brefeldin A; D007212:Indolizines; D009363:Neoplasm Proteins; C116614:ABCG2 protein, human; C037806:castanospermine; D054836:Indolizidines